Foghorn Therapeutics Past Earnings Performance
Past criteria checks 0/6
Foghorn Therapeutics's earnings have been declining at an average annual rate of -20.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 80% per year.
Key information
-20.1%
Earnings growth rate
42.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 80.0% |
| Return on equity | n/a |
| Net Margin | -288.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth
Apr 12
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too
Feb 22Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth
Dec 13Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues
Nov 07Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
Jun 14Foghorn Therapeutics: Selling For Less Than Cash Value
Oct 10Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286
Aug 23Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M
Aug 09Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity
Jun 02We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely
Apr 13Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?
Feb 27Revenue & Expenses BreakdownBeta
How Foghorn Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 34 | -98 | 32 | 0 |
| 30 Sep 23 | 33 | -103 | 33 | 0 |
| 30 Jun 23 | 22 | -115 | 33 | 0 |
| 31 Mar 23 | 21 | -112 | 32 | 0 |
| 31 Dec 22 | 19 | -109 | 31 | 0 |
| 30 Sep 22 | 16 | -109 | 29 | 0 |
| 30 Jun 22 | 9 | -109 | 27 | 0 |
| 31 Mar 22 | 5 | -105 | 24 | 0 |
| 31 Dec 21 | 1 | -101 | 22 | 0 |
| 30 Sep 21 | 1 | -93 | 20 | 0 |
| 30 Jun 21 | 1 | -85 | 17 | 0 |
| 31 Mar 21 | 1 | -78 | 14 | 0 |
| 31 Dec 20 | 0 | -69 | 11 | 0 |
| 30 Sep 20 | 0 | -63 | 8 | 0 |
| 30 Jun 20 | 0 | -58 | 8 | -20 |
| 31 Mar 20 | 0 | -54 | 7 | -10 |
| 31 Dec 19 | 0 | -51 | 7 | 0 |
Quality Earnings: FHTX is currently unprofitable.
Growing Profit Margin: FHTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FHTX is unprofitable, and losses have increased over the past 5 years at a rate of 20.1% per year.
Accelerating Growth: Unable to compare FHTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FHTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: FHTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.